Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure
- PMID: 8399662
Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure
Abstract
Seven intermittent peritoneal dialysis (IPD) patients were investigated before and after correction of anemia with recombinant human erythropoietin (r-HuEPO). When hematocrit exceeded 30%, the peritoneal equilibration test was performed at 1, 2, 4, 8 hours. Correction of anemia was associated with a mean value increment in creatinine and phosphate clearance in 1- and 2-hour dwells. Differences in clearance of sodium, potassium, and urea in protein loss and glucose absorption before and after r-HuEPO therapy were not statistically significant. Increased creatinine and phosphate clearance during short dwells can be effected in IPD patients.
Similar articles
-
Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.Am J Nephrol. 1990;10(2):128-36. doi: 10.1159/000168067. Am J Nephrol. 1990. PMID: 2349956 Clinical Trial.
-
Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO.Adv Perit Dial. 1992;8:467-70. Adv Perit Dial. 1992. PMID: 1361850
-
Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group.Int J Artif Organs. 1994 Apr;17(4):195-202. Int J Artif Organs. 1994. PMID: 8070941 Clinical Trial.
-
Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.Semin Nephrol. 1989 Mar;9(1 Suppl 1):16-21. Semin Nephrol. 1989. PMID: 2648516 Review.
-
Erythropoietin therapy in peritoneal dialysis patients.Perit Dial Int. 2000;20 Suppl 2:S178-82. Perit Dial Int. 2000. PMID: 10911666 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Medical